Go Back This article was viewed 87 times

Review Article


Cancer immunotherapy

Akhil JainSajjan Rajpurohit
Consultant Medical and Hemato-Oncologist, NewDelhi, India, Consultant Medical and Hemato-Oncologist, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India
Corresponding Author:

Akhil Jain

Consultant Medical and Hemato-Oncologist, NewDelhi, India
E-mail: akhiljaindr@gmail.com

Corresponding Author:

Akhil Jain

Consultant Medical and Hemato-Oncologist, NewDelhi, India
E-mail: akhiljaindr@gmail.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20183227

ABSTRACT


The era has begun where oncology meets immunology. The recent advancement in the field of molecular biology has led to the discovery of various pathways through which cancer establishes, proliferates, grows, and disseminates. These pathways provided major insight for targeting specific molecules with the targeted therapies that show predicted responses. This targeted therapy is usually referred to as immunotherapy. These immunotherapies possess and display a unique set of toxicities mainly immunologic in nature and different from chemotherapies. This article focuses on mechanisms of immune activity of the body and various therapies available to boost these mechanisms.
Keywords: Immune system, Immunotherapy, Targeted therapies

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.